Month: January 2024

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative...

JDRF Awards $9 Million US for Phase 3 Type 1 Diabetes Kidney Disease Clinical Trial, Joins The Kidney Foundation of Canada in Driving Research to Treat Kidney Disease

Planet 13 Enters into Definitive Agreement to Sell Its Medical Marijuana Treatment Center License in Florida in Connection with the Previously Announced Definitive Agreement to Acquire Vidacann

error: Content is protected !!